NEW YORK, May 9, 2017 /PRNewswire/ --
This morning, Stock-Callers.com covers the performances of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG), Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Cellectar Biosciences Inc. (NASDAQ: CLRB). According to a report on Investor's Business Daily, SPDR S&P Biotech rose more than 20% in the first three months of 2017. It has an average annual gain of 13.9% the past three years, and 21.3% the past five years. Learn more about these stocks by downloading their comprehensive and free reports at:
On Monday, shares in San Rafael, California headquartered BioMarin Pharmaceutical Inc. saw a drop of 3.72%, ending the day at $90.72. The stock recorded a trading volume of 1.91 million shares, which was above its three months average volume of 1.14 million shares. The Company's shares have advanced 4.41% in the last one month, 2.23% over the previous three months, and 9.51% since the start of this year. The stock is trading above its 200-day moving average by 0.72%. Moreover, shares of BioMarin Pharma, which develops and commercializes pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America, and internationally, have a Relative Strength Index (RSI) of 44.79.
On May 04th, 2017, BioMarin Pharma announced financial results for Q1 ended March 31st, 2017. GAAP net loss was $16 million, non-GAAP income was $35 million, and total revenues were $304 million. In addition, the Company had cash, cash equivalents and investments totaling $1.2 billion as of March 31st, 2017, compared to $1.4 billion on December 31st, 2016. BMRN complete research report is just a click away and free at:
Shares in Waltham, Massachusetts headquartered Eyegate Pharmaceuticals Inc. ended the day 7.94% lower at $1.89 with a total trading volume of 168,835 shares. In the previous three months and on an YTD basis, the stock has gained 24.34% and 15.95%, respectively. The Company's shares are trading above their 200-day moving average by 0.31%. Furthermore, shares of Eyegate Pharma, which focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye, have an RSI of 36.87.
On May 04th, 2017, Eyegate Pharma announced that the Company has submitted an Investigational Device Exemption (IDE) for the lead product in its cross-linked thiolated carboxymethyl hyaluronic acid platform, EyeGate Ocular Bandage Gel (EyeGate OBG). The IDE, if accepted, will enable the Company to initiate a second pilot study of EyeGate OBG for the acceleration of re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy. The complimentary report on EYEG can be downloaded at:
At the close of trading on Monday, shares in Dublin, Ohio headquartered Navidea Biopharmaceuticals Inc. finished 1.74% higher at $0.55 with a total trading volume of 293,087 shares. The stock has advanced 9.88% in the last one month and 5.65% over the previous three months. The Company's shares are trading below their 50-day moving average by 0.36%. Additionally, shares of Navidea Biopharma, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, have an RSI of 57.02.
On April 25th, 2017, Navidea Biopharmaceuticals announced that it has been invited to present data at two major upcoming conferences. The Company will present at the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging from June 10th to 14th, 2017 at the Colorado Convention Center in Denver. The Company will also present at the 2017 BIO International Convention from June 19th to 22nd, 2017 at the San Diego Convention Center in San Diego. Sign up for your complimentary research report on NAVB at:
Madison, Wisconsin headquartered Cellectar Biosciences Inc.'s shares recorded a trading volume of 100,585 shares at the end of yesterday's session. The stock closed the day 1.05% lower at $1.88. The Company's shares have advanced 15.34% in the previous three months and 54.10% on an YTD basis. The stock is trading below its 200-day moving average by 10.37%. Additionally, shares of Cellectar Biosciences, which engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer, have an RSI of 37.58.
On May 02nd, 2017, Cellectar Biosciences announced that management will host a teleconference and live webcast to report Q1 2017 financial results, followed by a review of corporate performance on May 11th, 2017 at 4:30 p.m. ET. The live and archived webcast of the call can be accessed via the Company's website. Get free access to your research report on CLRB at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA